Non-germinal center (non-GC) phenotype is an adverse prognostic factor in chemotherapy (CT)-treated diffuse large B-cell lymphoma (DLBCL) patients. To determine how high-dose therapy (HDT) supported with auto-SCT as first line therapy influences GC-associated outcome in young high-risk DLBCL patients GC and non-GC phenotypes were determined immunohistochemically from 63 patients. Of these, 29 primary high-risk DLBCL patients were treated with auto-SCT, whereas 34 CT-treated patients served as a control group. Consistent with previous studies, non-GC phenotype was associated with adverse outcome in CT-treated high-risk patients. In contrast, immunohistochemical classification by cell of origin did not associate with survival after auto-SCT. When the impact of treatment on the predictive value of cell of origin was analyzed, the non-GC patients, who received HDT, had a better failure-free survival (FFS) and overall survival (OS) than the patients treated with CT alone. In multivariate analyses, both age-adjusted International Prognostic Index (aaIPI) and treatment were independent prognostic factors for FFS and OS. For the patients with GC phenotype, the influence of auto-SCT on survival was not significant. The data imply that auto-SCT can overcome the adverse prognostic impact of the non-GC phenotype in patients with high-risk DLBCL and warrant additional prospective studies.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) characterized by heterogeneous clinical and biological features. 1 This aggressive malignancy has a rather poor outcome, as less than half of the patients can be cured with standard chemotherapy (CT). Currently, the International Prognostic Index (IPI), based on five clinical variables (age, performance status, stage, extranodal involvement and lactate dehydrogenase level), is the most important tool to predict survival 2 and to classify the patients into different risk groups. The age-adjusted IPI (aaIPI) (stage, performance status and lactate dehydrogenase) has also been used, particularly in studies adopting high-dose therapy (HDT) and auto-SCT. 3 As the outcome within individual IPI subgroups varies considerably, there is much interest in identifying biological factors, which could improve the outcome prediction.
The distinction of DLBCL according to cell of origin to germinal center (GC) and non-GC subgroups and their prognostic impact were initially investigated by gene expression profiling. 4, 5 The fact that the subgroups can also be classified immunohistochemically using a threemarker algorithm of CD10, Bcl-6 and MUM-1 has made this approach clinically more applicable. 6 Previous studies have shown that CT-treated DLBCL patients with GC phenotype have a better survival than the non-GC group of patients. [6] [7] [8] Interestingly, however, the prognostic significance of the GC and non-GC division and other GCmarkers, such as Bcl-6 is lost, when the patients are treated with immunochemotherapy. 9, 10 Likewise, the GC-and non-GC phenotypes seem not to correlate with outcome of relapsed and refractory DLBCL. 11 It is, therefore, evident that the type of treatment should be taken into consideration when the impact of biological factors for the prognosis of the disease is evaluated.
The best therapy for young high-risk DLBCL patients is unknown. While HDT and auto-SCT is accepted as standard therapy for patients with chemosensitive relapse, its role as part of the first line therapy for high-risk DLBCL is still a matter of debate. According to a recent metaanalysis, 12 no evidence for the improved survival was found for the low-risk patients. However, the evidence for the benefit of upfront HDT for high-risk patients was found to be inconclusive as some studies have reported improved and others reduced OS and FFS in comparison to conventional CT. 12 Thus, further studies are warranted. Identification of biologically relevant prognostic factors is also likely to clarify the role of upfront auto-SCT. To date, however, the studies on the prognostic impact of cell of origin in this setting have been miscellaneous. 13, 14 In this study, we examined whether HDT and auto-SCT after antracycline-based CT improved the outcomes in our institutes and how they influenced the GC-associated survival in young high-risk DLBCL patients.
Methods

Patients and treatments
The study consisted of 63 patients with de novo DLBCL. In the auto-SCT group, 29 patients received upfront intensive antracycline-based CT and auto-SCT in University Hospitals of Helsinki and Kuopio, Finland during 1994-2002. Most of the patients received a combination of CY, doxorubicin, vincristine and prednisone (CHOP) or CHOP combined with etoposide (CHOEP). Other CHOP-like treatment included MACOP-B (MTX, doxorubicin, CY, vincristine, prednisone and bleomycin) CT. As a high-dose therapy, the patients received either BEAC (carmustine, etoposide, cytarabine and CY) or BEAM (carmustine, etoposide, cytarabine and melphalan).
The patients serving as a control group (n ¼ 34) received antracyclin-based CT in University Hospital of Uppsala, Sweden during 1990-2004. In the control group, the majority of patients were treated with CHOP or CHO(E)P regimen. Other CHOP-like regimens included MACOP-B and VACOP-B (an MACOP-B-like regimen with etoposide, instead of MTX), EPOCH (etoposide, prednisone, vincristine, CY and doxorubicin) and CNOP (CY, mitoxantrone, vincristine and prednisone). All CT were administered as previously described in the original reports of these regimens. None of the patients in either group received rituximab in their first line therapy. The median follow-up time in the auto-SCT group was 95 months and in the control group 48 months. The clinical data were collected retrospectively and the comparison between patient groups was non-randomized. The study protocol and sampling were approved by Institutional Review Board and Finnish National Authority for Medicolegal Affairs.
Immunohistochemistry
For immunohistochemical stainings formaline-fixed, paraffin-embedded 4 mm tissue sections from samples taken at the time of diagnosis were used. After deparaffinization, the samples were rehydrated and treated in an autoclave in sodium citrate (pH 6.0) and washed with PBS. Stainings were performed at room temperature using CD10 (Novocastra Laboratories, Newcastle upon Tyne, UK) 1:200, Bcl-6 (Dako Cytomation, Glostrup, Denmark) 1:20 and MUM-1 (Dako) 1:100 dilutions. The immunoreactions were visualized with avidin-biotin-peroxidase ABCmethod and counterstained with Mayer's haematoxylin. As in previous studies, 6, 7, 9 sections were scored positive for respective stainings with a cutoff for 30% of positive lymphoma cells. The GC and non-GC classification was determined by the Hans algorithm. 6 If CD10 was positively stained, the sample was included to the GC-phenotype. If CD10 and Bcl-6 both stained negatively, the sample was of the non-GC-phenotype. If CD10 was negative but Bcl-6 positive, the MUM-1 staining determined the phenotype-MUM-1 negative cases were GC-and MUM-1 positive cases were non-GC phenotype. Two independent observers (HN and M-L K-L) evaluated the stainings. The reproducibility of the immunohistochemical data was as previously described. 9 Statistical analysis w 2 test was used to evaluate the differences in the frequency for the prognostics factors. Cox multivariate analysis was performed to test the prognostic value of the factors. Survival rates were estimated by the Kaplan-Meier method and differences compared with log-rank test. Overall survival (OS) was determined from the date of diagnosis until last follow-up or death. Failure-free survival (FFS) was evaluated from the date of diagnosis until relapse or death of any cause. OS and FFS were reported in months. Owing to poor outcome of some patients, a 2-year time point in the survival was most informative. All P-values were two tailed and a level of probability less than 0.05 was considered significant. All statistical analyses were carried out with SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
The study included 63 DLBCL patients. Of these, 29 patients received HDT and auto-SCT as a consolidation in their first line therapy, whereas 34 control patients treated with CT formed a control group. The patient characteristics are shown in Table 1 . The patients suffered from advanced disease primarily with a high aaIPI. They were under 65 years of age and suitable for HDT. The patients in the control group tended to be older than in the auto-SCT group (P ¼ 0.085), but the ranges of ages were equal. The auto-SCT group consisted of patients with higher aaIPI scores (P ¼ 0.003), indicating more aggressive features of their disease. Most of the patients received CHO(E)P or a third-generation regimen MACOP-B or VACOP-B, which according to previous studies have been shown to be equally efficient to CHOP. [15] [16] [17] The patients in the auto-SCT group tended to receive longer primary treatment than the control group (P ¼ 0.116). Immunohistochemically defined GC-and non-GC phenotypes were well balanced between the groups. When the patients were grouped according to cell of origin, the patient characteristics were also similar between the two treatment arms, as shown in the Supplement Tables 1 and 2 . The difference in aaIPI scores was also seen in the patients grouped according to GC and non-GC phenotypes, whereas the association of the longer primary treatment with the auto-SCT group was observed only in the non-GC subgroup.
To evaluate the outcome in response to different treatments, a two-year FFS and OS rates were estimated by Kaplan-Meier method and the differences were compared with log-rank test. Despite higher aaIPI scores, the patients in the auto-SCT group had a better survival than the control patients (FFS 64 vs 46%, P ¼ 0.02) ( Figure 1a , Table 2 ). A non-significant difference for OS was also observed (75 vs 63%, P ¼ 0.183) (Figure 1b , Table 2 ). A smaller difference in OS rates is likely to be due to an intensification of the second line treatment in the primary CT group. The aaIPI score tended to predict survival for both treatment groups. The patients with low aaIPI had a superior survival in comparison to the highrisk patients, but due to small number of the patients with low aaIPI, the result was not significant (data not shown).
To assess the prognostic impact of GC-and non-GC phenotypes for the outcome in response to conventional and HDT, survival rates were evaluated in the control and auto-SCT groups. Consistent with previous studies, 6,7 the CT-treated patients with non-GC phenotype had a very poor outcome in comparison to the survival of the patients with GC phenotype. The two-year FFS was 66% for the GC group as compared to 20% for non-GC patients (Po0.001) (Figure 2, Table 2 ). A significant difference in OS was also observed (77 vs 47%, P ¼ 0.004) ( Table 2) . However, in the auto-SCT group, no difference in the clinical outcome was observed between GC-and non-GC groups (FFS 67 vs 62%, P ¼ 0.804; OS 83 vs 61%, P ¼ 0.585) (Figure 2, Table 2 ). We further evaluated the effect of treatment on the predictive value of cell of origin distinction by comparing the outcomes in the GC and non-GC subgroups. In the non-GC group, the auto-SCT-treated patients had a significantly better two-year survival rates than the control group (FFS 62 vs 20%, Po0.001) (Figure 2 ). The two-year OS in the non-GC group was 69% for the auto-SCT group and 47% for the control group (P ¼ 0.009). In contrast, the treatment had no significant influence on the survival of the patients in the GC group (FFS 67 vs 66%, P ¼ 0.821; OS 83 vs 77%, P ¼ 0.414) (Figure 2) .
Cox multivariate analysis confirmed the prognostic effect of auto-SCT in the non-GC group (Table 3) . In the univariate analysis, aaIPI and treatment were significant prognostic factors for FFS and OS, and both factors remained statistically significant for FFS also in multivariate analysis.
Discussion
In this study, we demonstrate that HDT and auto-SCT can improve the outcome of high-risk DLBCL patients in comparison with CHOP-like CT. However, the benefit of auto-SCT is only seen for patients with a non-GC center phenotype and treatment. P-values for different comparisons are as follows: in the control patients for the GC group as compared to non-GC patients, Po0.001; in the auto-SCT group for the GC group as compared to non-GC patients, P ¼ 0.804; in the non-GC subgroup for the auto-SCTtreated patients as compared to the control group, Po0.001 and in the GC subgroup for the auto-SCT-treated patients as compared to the control group, P ¼ 0.821. DLBCL, diffuse large B-cell lymphoma; FFS, failure-free survival. phenotype. Thus, dose intensification seems to eliminate the adverse prognostic impact of the non-GC phenotype in high-risk DLBCL. On the basis of gene expression profiling studies in DLBCL, the cell of origin distinction has been identified as an important determinant of survival. The leukemia/ lymphoma molecular profiling project determined three major signatures with different outcomes. 5 Two of these signatures called activated B-cell like or non-GC phenotype and GC phenotype can also be classified with immunohistochemistry. 6 According to several studies, the patients with immunohistochemically defined GC phenotype have a superior outcome in response to standard CHOP-like CT. 6, 7, 9 However, not all studies have been able to confirm the prognostic significance of the phenotypes. 18, 19 Thus far, the data on the impact of cell of origin for survival in response to HDT and auto-SCT are also inconsistent. While van Imhoff et al. 13 showed that primary high-risk patients with GC phenotype have a better outcome than the non-GC group, we and others 14 could not observe such a difference. In all studies, the baseline clinical characteristics were similar. However, treatment was not identical and GC and non-GC phenotypes were not equally distributed. These together with other unknown intrinsic properties and technical factors such as quantification methods might influence the results.
Using a similar scoring method and 30% cutoff levels as Hans et al., 6 we could reproduce the association of non-GC phenotype with unfavorable FFS and OS among the highrisk patients who are not receiving HDT and auto-SCT as part of their first line therapy. However, our major interest was to determine whether the cell of origin distinction has prognostic impact for DLBCL patients consolidated with HDT and auto-SCT. The finding that the difference in survival between GC and non-GC phenotypes was lost illustrates that HDT and auto-SCT have a strong influence on the prognostic impact of cell of origin in DLBCL. This together with previous data on both primary and relapsed patients 11, 14 encourages us to believe that dose intensification of CT can overcome the prognostic effect of unfavorable non-GC phenotype. Interestingly, addition of rituximab to first line CT also eliminates the adverse impact of non-GC phenotype for survival. 9 Although this study is not a concurrent comparison of treatment options and any conclusions between nonrandomized groups may be subject to differences in observed and unobserved prognostic factors, it is unlikely that the differences in outcome seen in control and auto-SCT groups are caused by factors other than treatment. While both negative and positive impact of upfront HDT and auto-SCT on survival have been reported, [20] [21] [22] [23] [24] our findings are in line with positive studies, which suggested that especially young high-risk patients benefit from upfront HDT. 21, 24 The finding showing that the benefit of HDT and auto-SCT is only seen in the non-GC subgroup is also important as it highlights the fact that two phenotypes are biologically and clinically distinct.
The mechanism by which the HDT and auto-SCT improve the outcomes only in the non-GC group is unknown, but it could be related to nuclear factor (NF-kB)-related chemoresistance. 25 Tumor cells, in which NF-kB is constitutively active, are highly resistant to chemotherapeutic drugs, and inhibition of NF-kB activity in these cells increases their sensitivity to CT. 26 Considering that NF-kB pathway is constitutively active specifically in non-GC lymphomas, 27 it can, therefore, be speculated that HDT overcomes the NF-kB-mediated chemoresistance.
Given the efficacy and low toxicity of rituximab, the relevance of any results from upfront HDT and auto-SCT may be considered questionable during the rituximab era of lymphoma therapies. However, the mechanism of actions of rituximab and HDT are different and currently no data are available to show whether rituximab evades the need for upfront HDT or further improves its efficacy. According to previously published data on R-CHO(E)P-treated patients aged less than 60 years with risk factors (IPI 1 and bulk), 28 as well as our unpublished experience on 26 R-CHO(E)P-treated young high-risk patients, the FFS at 3 years is estimated to be between 63 and 74% only. These outcomes emphasize the presence of a subpopulation of patients both in GC and non-GC subgroups, who do not respond to rituximab or acquire resistance and need other treatment options. The 62% two-year FFS identified after HDT in the subgroup of non-GC patients together with our previous finding that a significant benefit of immunochemotherapy is only seen for the patients having non-GC phenotype may support a role for rituximab besides HDT in this subgroup. Thus, future studies should address the value of cell of origin and other biological characteristics for identifying the comparative advantages of HDT and rituximab.
In conclusion, we have shown that the strong adverse impact of non-GC phenotype can be overcome by upfront HDT and auto-SCT in high-risk DLBCL. Our findings further demonstrate that the benefit of HDT is primarily seen among the patients with non-GC phenotype. Although the results have to be confirmed in a larger group of unselected patients, they could lead to improvements in risk stratification and thus provide possibility of better therapy and improved future trial design.
